Blue Cross Blue Shield notified The University of Texas MD Anderson Cancer Center it will end its Letter of Agreement for Medicare Advantage and Texas Managed Medicaid services, effective Nov. 1, 2024. This does not impact UT System or Texas A&M System retirees on these plans, patients on BCBS commercial or managed care insurance plans, or Medicare patients with a BCBS Medicare Supplemental Plan.
While MD Anderson welcomes...
The James P. Allison Institute at The University of Texas MD Anderson Cancer Center hosted its second annual scientific...
The University of Texas MD Anderson Cancer Center and Summit Therapeutics, Inc. today announced a strategic five-year collaboration agreement...
The University of Texas MD Anderson Cancer Center and Rice University today announced the creation of the Cancer Bioengineering Collaborative to develop innovative technologies and bioengineering approaches to improve cancer research, diagnosis and treatment.
Led by Rice’s Gang Bao, Ph.D., and MD Anderson’s Jeffrey Molldrem, M.D., the initiative aims to foster collaboration between the two institutions on fundamental and translational...
ABSTRACTS: LB3439, LB3442, S131, S132, S136, S164, S222
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases...
The University of Texas MD Anderson Cancer Center and Sibylla Biotech today announced a strategic collaboration agreement to discover and...
The James P. Allison Institute at The University of Texas MD Anderson Cancer Center today announced the appointment of its newest members,...
The University of Texas MD Anderson Cancer Center and Replay today announced that the Food & Drug Administration (FDA) has issued...
The University of Texas MD Anderson Cancer Center and CureVac N.V. today announced a co-development and licensing agreement to develop novel...
The Institute for Data Science in Oncology (IDSO) at The University of Texas MD Anderson Cancer Center today announced the appointment...